Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Open-Label Study of Volociximab (M200) in Patients With Metastatic Renal Cell Carcinoma

NCT00100685 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00100685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00100685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Open-Label Study of Volociximab (M200) in Patients With Metastatic Renal Cell Carcinoma
Lead sponsor
Abbott
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2005
Completion date
December 31, 2007
Enrollment
48 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastases, renal cell carcinoma